Vical (VICL) to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives
Tweet Send to a Friend
Vical Incorporated (Nasdaq: VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
